Navigation Links
Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
Date:7/24/2013

NORCROSS, Ga., July 24, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient has been successfully dosed in a Phase 1 clinical trial of GR-MD-02. The first-in-man study will evaluate the safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis.

GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin proteins play a major role in diseases that involve scaring of organs such as cancer, and inflammatory and fibrotic disorders. The drug binds to galectin proteins and disrupts their function. Preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis.

"The successful first patient dosing in the clinical trial of GR-MD-02 is a critical milestone in Galectin's development program. There are currently no treatments for fatty liver disease with advanced fibrosis; this milestone takes us one step closer to bringing a first-in-class treatment to the millions of Americans suffering from this silent epidemic," said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "We anticipate that enrollment of the first cohort of eight patients in the Phase 1 trial will be complete by late summer with initial safety and tolerability results available following the 70 day study period and analysis of the data."

The Phase 1 multi-center, partially-blinded clinical trial will be conducted in 24 patients with fatty liver disease and advanced fibrosis who will r
'/>"/>

SOURCE Galectin Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
2. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
3. Cell Therapeutics to Report Second Quarter Financial Results after Market on July 31, 2013
4. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
5. Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
6. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
7. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
8. Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
11. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... ALEXANDRIA, Va. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... in the Food and Drug Administration,s (FDA,s) draft ... including reference products and biosimilars, to bear a ... years, AMCP has been seeking a decision from ... joined 18 diverse health care stakeholders urging the ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... and WILMINGTON, Del., Dec. 21 Eli Lilly and ... (Nasdaq: INCY ) announced today that they have ... for the development and commercialization of Incyte,s oral JAK1/JAK2 ... and autoimmune diseases. The lead compound, INCB28050, is currently ...
... , CARLSBAD, Calif., Dec. 21 Isis ... will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. ... license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). ... and OncoGenex that has completed a successful Phase 2 program ...
Cached Medicine Technology:Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 2Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 3Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 4Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 5Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 6Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... , ... Lizzie’s Lice Pickers , a company that offers professional live ... offering lice head checks for just $10, which is a significant discount from the ... their lice treatment products. “With kids returning to school, it is very important to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes with ... 25 years working in operations, purchasing and management for some of the nations ...
(Date:8/29/2015)... VA (PRWEB) , ... August 30, 2015 , ... ... Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... more than a simple digital handwritten signature. , Clinical trial sites ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... parents worry babies get ,too much too soon, but ... May 24 (HealthDay News) -- Some American parents are ... they,re worried that their infants are getting too many ... issues. , The issue has been especially persistent when ...
... ... project management support and peer-to-peer learning opportunities to aid in transformation process, ... Leawood, ... Physicians, today announced a new service offering aimed at helping small primary care ...
... Knowledge regarding environmental factors influencing the risk of ... this area. In particular, the roles of smoking and ... this month in the Journal of Alzheimer,s Disease ... the risk of Alzheimer,s disease, particularly in women who ...
... ... new facility , ... (Vocus) May 24, 2010 -- AthletiCo Physical and Occupational Therapy announces the relocation ... The new facility is located in the Hillcrest Center across the street from the Worden ...
... ... ... InPro Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) ... certifies the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior ...
... ... its expansion into new office space in the Century Square building in downtown Seattle, Washington. ... Vancouver, B.C., supports a number of employees on the East Coast and in the Midwest ... ...
Cached Medicine News:Health News:No Benefit Seen in Delaying Infant Vaccinations 2Health News:No Benefit Seen in Delaying Infant Vaccinations 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 4Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 2Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 3Health News:InPro Becomes AAHID Industry Partner 2Health News:Quorum Review IRB Commemorates New Office with Ribbon Cutting Ceremony 2
... 64 is the ultimate CT solution ... Our system fuses the latest and ... applications delivering unprecedented image quality. It ... to meet the requirements for cardiac ...
... MONO-plus test uses direct ... the qualitative detection of ... whole blood, serum or ... waived whole blood kit ...
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK...
... Made with elastic fabric, these head cap ... need to begin testing. Each Electro-Cap System ... the International 10-20 System. When you place ... are using with your head cap system ...
Medicine Products: